A Look At IDEX (IEX) Valuation After Strong Q4 Results And Ongoing Buybacks

IDEX (IEX) shares have been reacting to a cluster of recent developments, including fourth quarter earnings, completion of a long running buyback program, and the planned exit of its Chief Strategy and Innovation Officer.

See our latest analysis for IDEX.

The recent 30.14% 3 month share price return and 17.51% year to date share price return suggest positive momentum has been building, even though the 3 year total shareholder return of a 5.13% decline contrasts with a 13.54% gain over five years.

If IDEX’s recent earnings and buybacks have your attention, it could be a good moment to broaden your watchlist and check out 23 top founder-led companies.

With IDEX stock up strongly over the past quarter and trading around US$210.41, investors are left weighing its roughly 16% intrinsic discount estimate against recent earnings and buybacks, and asking whether this is a genuine opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 5.9% Undervalued

At a last close of $210.41 against a most followed fair value estimate of $223.54, the narrative implies modest upside driven by specific growth and margin assumptions.

The company is implementing proactive cost-saving measures, targeting $20 million in savings on top of previous initiatives. This focus on platform optimization and organizational delayering may improve net margins by reducing operating expenses.

Read the complete narrative.

Want to see what really sits behind that fair value gap? The narrative leans heavily on steadier revenue growth, thicker margins, and a richer future earnings multiple. Curious which of those assumptions does the heavy lifting in the model? The full breakdown spells it out clearly.

Result: Fair Value of $223.54 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are still clear pressure points, including tariff impacts on costs and softer demand in sectors like semiconductor and agriculture, which could challenge this upbeat narrative.

Find out about the key risks to this IDEX narrative.

Another Angle On Valuation

So far, the story leans on future earnings power to argue IDEX looks modestly undervalued. On a simple P/E lens, though, the picture is tighter. IDEX trades on 32.6x earnings, compared with a fair ratio of 26.7x, the US Machinery industry at 29.9x, and peers at 30.2x.

That premium suggests the market is already paying up for quality and resilience, which can limit upside if the growth narrative does not play out as expected. The question for you is whether those extra few turns of P/E feel like a margin of safety or a source of valuation risk from here.

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own IDEX Narrative

If this version of the IDEX story does not fully match your view, or you would prefer to build on your own findings, you can create a custom thesis in just a few minutes by starting with Do it your way.

A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding IDEX.

Looking for more investment ideas?

Do not stop your research with one company. Broaden your opportunity set with focused stock ideas that match the way you like to invest.

• Target resilience first by scanning companies with stronger finances using our solid balance sheet and fundamentals stocks screener (44 results) so you are not guessing on balance sheet strength.
• Hunt for value by spotting potential mispriced opportunities through the 54 high quality undervalued stocks and see which names stand out on quality and price.
• Prioritize stability by checking companies highlighted in the 83 resilient stocks with low risk scores before sentiment shifts and others start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com